Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsus
AssigneeA+ Science AB (publ)
InventorsKjell Olmarker, Björn Rydevik
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-α comprising an effective amount of a TNF-α inhibitor, as well as a method for treatment of such disorders, and the use of TNF-α inhibitors in the preparation of pharmaceutical compositions for such treatment.
Claims27
A method of treating a nerve disorder mediated by nucleus pulposus in a mammal in need of such treatment wherein said nerve disorder mediated by nucleus pulpous is caused by the liberation of TNF-α and compounds triggered by the liberation of or presence of TNF-α comprising the step of administering a TNF-α inhibitor wherein said TNF-α inhibitor is a metalloproteinase inhibitor excluding methylprenisolone to a mammal in need of such treatment thereby inhibiting TNF-α and treating said disorder.
Dependencies are inferred from the claim text.